BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35460532)

  • 1. Molecular and immunohistochemical characterisation of mesothelioma of the tunica vaginalis
    Anderson WJ; Sholl LM; Fletcher CDM; Schulte S; Wang LJ; Maclean FM; Hirsch MS
    Histopathology; 2022 Jul; 81(1):65-76. PubMed ID: 35460532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion.
    Hiroshima K; Wu D; Hamakawa S; Tsuruoka S; Ozaki D; Orikasa H; Hasegawa M; Koh E; Sekine Y; Yonemori Y; Nabeshima K; Tsuji S; Miyagi Y; Imai K
    Diagn Cytopathol; 2021 May; 49(5):622-632. PubMed ID: 32441895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAF7 mutations and immunohistochemical study of uterine adenomatoid tumor compared with malignant mesothelioma.
    Itami H; Fujii T; Nakai T; Takeda M; Kishi Y; Taniguchi F; Terada C; Okada F; Nitta Y; Matsuoka M; Sasaki S; Sugimoto S; Uchiyama T; Morita K; Kasai T; Kawaguchi R; Ohbayashi C
    Hum Pathol; 2021 May; 111():59-66. PubMed ID: 33667423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
    Berg KB; Dacic S; Miller C; Cheung S; Churg A
    Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
    Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Iwasaki A; Nabeshima K
    Mod Pathol; 2020 Feb; 33(2):235-244. PubMed ID: 31231129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
    Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
    Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features.
    Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kasai T; Hiroshima K; Kushitani K; Takeshima Y; Kawahara K; Iwasaki A; Nabeshima K
    Ann Diagn Pathol; 2022 Oct; 60():152004. PubMed ID: 35797798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
    Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
    Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
    Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB; Churg AM; Cheung S; Dacic S
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of diffuse malignant peritoneal mesothelioma.
    Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR
    Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma.
    Terra S; Roden AC; Yi ES; Aubry MC; Boland JM
    Am J Clin Pathol; 2022 Jan; 157(1):33-39. PubMed ID: 34463336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
    Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
    Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.
    Erber R; Warth A; Muley T; Hartmann A; Herpel E; Agaimy A
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):67-73. PubMed ID: 30640754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma.
    Chapel DB; Dubuc AM; Hornick JL; Sholl LM
    Histopathology; 2021 Jun; 78(7):1032-1042. PubMed ID: 33387364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
    Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
    Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.
    Chapel DB; Hornick JL; Barlow J; Bueno R; Sholl LM
    Mod Pathol; 2022 Oct; 35(10):1383-1397. PubMed ID: 35459788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
    Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
    Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Iwasaki A; Nabeshima K
    Cancer Cytopathol; 2021 Jul; 129(7):526-536. PubMed ID: 33493384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.